Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2637-2644

  Patick, A K ^a   Duran, M ^b   Cao, Y ^b   Shugarts, D ^c   Keller, M R ^a   Mazabel, E ^a   Knowles, M ^a   Chapman, S ^a   Kuritzkes, D R ^c   Markowitz, M ^b  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEINASE INHIBITION; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS ISOLATION;

EID: 0031692748     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2637     Document Type: Article

References (50)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Appell, K. 1997. Inhibitors of HIV-1 protease, p. 1-39. In P. Veerapandian (d.), Structure-based drug design. Marcel Dekker, Inc., New York, N.Y.
3. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiretroviral therapy for HIV infection in 1947. JAMA 277:1962-1969.
4. Chen, Z., H. B. Schock, D. Hall, E. Chen, and L. C. Kuo. 1995. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270:21433-21436.
5. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1011-1017.
6. Conant, M., M. Markowitz, A. Hurley, D. Ho, J. Peterkin, and S. Chapman. 1996 A randomized phase II dose range-finding study of the HIV protease inhibitor VIRACEPT® as monotherapy in HIV positive patients, abstr. Tu.B.2129. In Abstracts of the XI International Conference on AIDS. Vancouver, Canada.
7. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, and M. Shivaprakash. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
8. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, Randi Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
9. Craig, J. C., I. B. Duncan, S. Gilbert, H. Jacobsen, R. Jupp, A. Moffatt, E. Race, N. A. Roberts, J. S. Mills, J. Mous, J. Sheldon, P. W. Tomlinson, and L. N. Whittaker. 1996. Treatment with saquinavir (Invirase™) should leave the majority of patients the option to use other HIV proteinase inhibitors, p. 32. In Abstracts of the Fifth International Workshop on HIV Drug Resistance, Whistler, Canada.
10. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. G. Aguado, J. Garcia De Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. M. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
11. Erickson, J. W., and S. K. Burt. 1996. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36:545-571.
12. Gathe, J., Jr., B. Burkhardt, P. Hawley, M. Conant, J. Peterkin, and S. Chapman. 1996. A randomized phase II study of VIRACEPT®, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone, abstr. Mo.B.413. In Abstracts of the XI International Conference on AIDS, Vancouver, Canada.
13. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persona with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
14. Henry K., E. Kane, H. Melroe, J. Simpson, A. Patick, and D. Winslow. 1997. Experience with a ritonavir/saquinavir based regimen for the treatment ot HIV-infection in subjects developing increased viral loads while receiving nelfinavir, abstr. 1-204. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. American Society for Microbiology, Washington, D.C.
15. Henry, K., A. Lamarca, R. Myers, and S. Chapman for the Viracept Collaborative Study Group and Agouron Pharmaceuticals. 1997. The safety of Viracept® (nelfinavir mesylate, NVR) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with either d4T or AZT/3TC, abstr. 240. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
16. Hertogs, K., A. Patick, P. Schel, A. Van Cauwenberge, M. Markowitz, U. Kuritzkes, B. Anderson, and R. Pauwels. 1997. Phenotypic resistance testing (PR-RT-Antivirogram™) of clinical HIV-1 isolates confirms the unique and different resistance pathway of nelfinavir, latebreaker abstr. 906. In Abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, Germany.
17. Ho, D. D., T. Tovoshima, H. Mo, D. J. Kempf, D. Norbeck, C.-M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodenciency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
18. Ives, K. J., H. Jacobsen, S. A. Galpin, M. M. Garaev, L. Dorrell, J. Mous, K. Bragman and J. N. Weber. 1997. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J. Antimicrob. Chemother. 39:771-779.
19. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor RO 31-8959. Virology 206:527-34.
20. Jacobsen, H., M. Hänggi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella and J. Mous. 1996. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J. Infect. Dis. 173:1379-1387.
21. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, The RV-43 Study Group, and The Aids Clinical Trials Group, Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
22. Kaldor, S. W., V. J. Kalish, J. F. Davies II, B. V. Shelly, J. E. Fritz, K. Appelt, J. A. Burgess, K. M. Campanale, N. Y. Chirgadze, D. K. Clawson, B. A. Dressman, S. D. Hatch, D. A. Khalil, M. B. Kosa, P. P. Lubbehusen, M. A. Myesing, A. K. Patick, S. H. Reich, K. S. Su, and J. H. Tatlock. 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:3979-3985.
23. Kozal, M. J., N. Shah, N. Shen, R. Yang, R. Fucini, T. C. Merigan, D. D. Richman, D. Morris, E. Hubbell, M. Chee, and T. R. Gingeras. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med. 2:753-759.
24. Kozal, M., N. Leahy, J. Ross, N. Swack, and J. Stapleton. 1997 Prevalence of protease inhibitor (PRI) and reverse transcriptase inhibitor (RTI) drug-resistance mutations in a rural Iowa HIV+ population: implication for treatment, abstr. 9. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
25. Lech, W. J., G. Wang, Y. L. Yang, Y. Chee, K. Dorman, D. McCrae, L. C. Lazzeroni, J. W. Erickson, J. S. Sinsheimer, and A. H. Kaplan. 1996. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043.
26. Markowitz, M., H. Mo, D. J. Kempf,. D. W. Norbeck, T. Narayana Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
27. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
28. Markowitz, M., D. Winslow, Y. Cao, A. Hurley, R. O'Donavan, and B. Anderson. 1997. Triple therapy with nelfinavir in combination with AZT and 3TC in 12 antiretroviral-naïve subjects chronically infected with HIV-1. In Abstracts of the 10th International Conference on Antiviral Research, Atlanta, Ga.
29. Markowitz, M., M. Conant, A. Hurley, R. Schluger, M. Duran, J. Peterkin, S. Chapman, A. Patick, A. Henricks, G. J. Yuen, W. Hoskins, N. Clendennin, and D. D. Ho. A preliminary evaluation of nelfinavir mesylate, an inhibitor of HIV-1 protease, to treat HIV infection. J. Infect. Dis., in press.
30. McDonald, C. K., and D. R. Kuritzkes. 1997. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157:951-959.
31. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
32. Myers, G., S. Wain-Hobson, L. E. Henderson, B. Korber, K.-T. Jeang, and G. N. Pavlakis. 1993. Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, N.Mex.
33. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity of hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
34. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P.-F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
35. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
36. Patick, A. K., T. J. Boritzki, and L. A. Bloom. 1997. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vivo. Antimicrob. Agents Chemother. 41:2159-2164.
37. Patick, A. K., M. Duran, Y. Cao, T. Ho, P. Zhou, M. R. Keller, S. Chapman, R. Anderson, D. Kuritzkes, D. Shugarts, D. Ho, and M. Markowitz. 1997. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T, AZT and 3TC, abstr. 10. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
38. Patick, A. K., D. Kuritzkes, V. A. Johnson, D. Shugarts, M. Bakhtiari, K. E. Potts, A. Farnsworth, R. Anderson, J. L. Koel, J. D. Hazelwood, C. D. Nail, M. Duran, M. Markowitz, D. Ho, and D. Richman. 1997. Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other HIV-1 protease inhibitors, abstr. 18. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Fla.
39. Powderly, W., M. Sension, M. Conant, A. Stein, and N. Clendeninn. 1997. The efficacy of VIRACEPT® (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC, abstr. 370. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
40. Rose, R. E., Y.-F. Gong, J. A. Greytok, C. M. Bechtold, B. J. Terry, B. S. Robinson, M. Alam, R. J. Colonno, and P.-F. Lin. 1995. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
41. Saag, M., M. Gersten, Y. Chang, S. L. Greenberg, G. Yu, and N. J. Clendeninn. 1997. Long term virological and immunological effect of the HIV protease inhibitor, Viracept (nelfinavir mesylate) in combination with zidovudine and lamivudine, abstr. In Abstracts of the Infectious Disease Society of America, San Francisco, Calif.
42. + T-cell counts in HIV-counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050.
43. Schmit, J.-C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter, E. DeClercq, and A.-M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for one year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
44. Schock, H. B., V. M. Garsky, and L. C. Kuo. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. J. Biol. Chem. 271:31957-31963.
45. Smidt, M. L., K. E. Potts, S. P. Tucker, L. Blystone, T. R. Steibel, W. C. Stallings, J. J. McDonald, D. Pillay, D. D. Richman, and M. L. Bryant. 1996. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor sc-55389a. Antimicrob. Agents Chemother. 41:515-522.
46. Tebas, P., E. Kane, M. Klebert, J. Simpson, W. G. Powderly, and K. Henry. 1998. Virologie responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir, abstr. 510. p. 175. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill.
47. Tisdale, M., R. E. Myers, B. Maschera, N. R. Parry, N. M. Oliver, and E. D. Blair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
48. + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res. 29:91-93.
49. Williams, I. G. 1996. Use of protease inhibitors. J. HIV Combin. Ther. 1:4-7.
50. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors ot HIV-1 protease. Annu. Rev. Biochem. 62:543-585.